ZA200809529B - Melatonin agonist treatment - Google Patents
Melatonin agonist treatmentInfo
- Publication number
- ZA200809529B ZA200809529B ZA200809529A ZA200809529A ZA200809529B ZA 200809529 B ZA200809529 B ZA 200809529B ZA 200809529 A ZA200809529 A ZA 200809529A ZA 200809529 A ZA200809529 A ZA 200809529A ZA 200809529 B ZA200809529 B ZA 200809529B
- Authority
- ZA
- South Africa
- Prior art keywords
- agonist treatment
- melatonin agonist
- melatonin
- treatment
- agonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74784706P | 2006-05-22 | 2006-05-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200809529B true ZA200809529B (en) | 2009-12-30 |
Family
ID=38723632
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200809529A ZA200809529B (en) | 2006-05-22 | 2008-11-07 | Melatonin agonist treatment |
Country Status (17)
Country | Link |
---|---|
US (6) | US20090105333A1 (pt) |
EP (1) | EP2028937B2 (pt) |
JP (5) | JP2009538332A (pt) |
KR (2) | KR101571163B1 (pt) |
AU (3) | AU2007253701A1 (pt) |
BR (1) | BRPI0712206A2 (pt) |
CA (2) | CA2666293C (pt) |
CY (1) | CY1120433T1 (pt) |
DK (1) | DK2028937T4 (pt) |
ES (1) | ES2532849T5 (pt) |
MX (1) | MX2008014841A (pt) |
NL (1) | NL300795I2 (pt) |
PL (1) | PL2028937T5 (pt) |
PT (1) | PT2028937E (pt) |
RU (1) | RU2488392C2 (pt) |
WO (1) | WO2007137244A1 (pt) |
ZA (1) | ZA200809529B (pt) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2532849T5 (es) † | 2006-05-22 | 2018-10-18 | Vanda Pharmaceuticals Inc. | Tratamiento con agonista de la melatonina |
JP5590676B2 (ja) * | 2007-09-13 | 2014-09-17 | ヴァンダ ファーマシューティカルズ インコーポレイテッド | Per3vntr遺伝子型に基づく睡眠パラメータ及び睡眠誘導化合物に対する応答の予測 |
EP2453891A1 (en) * | 2009-07-16 | 2012-05-23 | Vanda Pharmaceuticals Inc. | Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia |
ES2646197T3 (es) | 2012-01-26 | 2017-12-12 | Vanda Pharmaceuticals Inc. | Tratamiento de trastornos del ritmo circadiano |
US11918557B2 (en) | 2012-01-26 | 2024-03-05 | Vanda Pharmaceuticals Inc. | Treatment of circadian rhythm disorders |
BR112015014619A2 (pt) * | 2012-12-18 | 2017-07-11 | Vanda Pharmaceuticals Inc | tratamento de transtornos do ritmo circadiano |
US11090285B2 (en) | 2013-11-12 | 2021-08-17 | Vanda Pharmaceuticals Inc | Treatment of circadian rhythm disorders |
US10376487B2 (en) | 2013-11-12 | 2019-08-13 | Vanda Pharmaceuticals Inc. | Method of treatment |
WO2015117048A1 (en) | 2014-01-31 | 2015-08-06 | Vanda Pharmaceuticals Inc. | Treatment of circadian rhythm disorders |
FI3188727T3 (fi) | 2014-09-02 | 2023-02-20 | Tasimelteoni smith-magenisin oireyhtymän hoitamiseksi | |
US20210059973A1 (en) | 2017-08-02 | 2021-03-04 | Vanda Pharmaceuticals Inc. | Treatment of Affective Disorders |
EP3761974A1 (en) | 2018-03-04 | 2021-01-13 | Vanda Pharmaceuticals Inc. | Treatment of disorders with tasimelteon |
JP7432884B2 (ja) * | 2018-03-26 | 2024-02-19 | パナソニックIpマネジメント株式会社 | サポートシステム、機器制御システム、サポートシステムの作動方法、及び、機器制御システムの作動方法 |
CA3112202A1 (en) * | 2018-09-12 | 2020-03-19 | Vanda Pharmaceuticals Inc. | Improving sleep or post-sleep performance |
CN113993516A (zh) * | 2019-02-13 | 2022-01-28 | 万达制药公司 | 改善睡眠的方法 |
EP3989964A1 (en) | 2019-06-29 | 2022-05-04 | Vanda Pharmaceuticals Inc. | Tasimelteon use in treating sleep aberrations |
JP2023506225A (ja) | 2019-12-13 | 2023-02-15 | バンダ・ファーマシューティカルズ・インコーポレイテッド | 液体タシメルテオン製剤及びそれを使用する方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0126630B1 (en) * | 1983-05-18 | 1987-09-16 | Monash University | The use of melatonin for the manufacture of a medicament |
US5242941A (en) † | 1990-12-04 | 1993-09-07 | State Of Oregon | Methods of treating circadian rhythm disorders |
IT1251544B (it) * | 1991-05-13 | 1995-05-17 | Gabriele Biella | Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico |
GB9416884D0 (en) * | 1994-08-20 | 1994-10-12 | Danbiosyst Uk | Drug delivery compositions |
RU2188006C2 (ru) * | 1995-03-06 | 2002-08-27 | Ново Нордиск А/С | Стимуляция мейоза |
WO1998025606A1 (en) | 1996-12-10 | 1998-06-18 | Bristol-Myers Squibb Company | Benzodioxole, benzofuran, dihydrobenzofuran, and benzodioxane melatonergic agents |
US5776969A (en) * | 1997-02-27 | 1998-07-07 | Eli Lilly And Company | Treatment of sleep disorders |
WO2005063240A1 (en) * | 2003-12-22 | 2005-07-14 | The Brigham And Women's Hospital, Inc. | Methods and compositions for treatment of hypertension |
AU2004308962A1 (en) * | 2003-12-24 | 2005-07-14 | Sepracor Inc. | Melatonin combination therapy for improving sleep quality |
BRPI0614701A2 (pt) * | 2005-07-29 | 2011-04-12 | Vanda Pharmaceuticals Inc | usos de um composto para melhorar a vigìlia e composições farmacêuticas |
ES2532849T5 (es) † | 2006-05-22 | 2018-10-18 | Vanda Pharmaceuticals Inc. | Tratamiento con agonista de la melatonina |
ES2646197T3 (es) * | 2012-01-26 | 2017-12-12 | Vanda Pharmaceuticals Inc. | Tratamiento de trastornos del ritmo circadiano |
US10376487B2 (en) * | 2013-11-12 | 2019-08-13 | Vanda Pharmaceuticals Inc. | Method of treatment |
EP3470405A1 (en) * | 2014-02-12 | 2019-04-17 | Vanda Pharmaceuticals Inc. | Highly purified pharmaceutical grade tasimelteon |
WO2016066631A1 (en) † | 2014-10-28 | 2016-05-06 | Sandoz Ag | Pharmaceutical composition consisting of ceftaroline fosamil acetic acid solvate particles and arginine particles, both having a specific particle size distribution |
-
2007
- 2007-05-22 ES ES07797634.8T patent/ES2532849T5/es active Active
- 2007-05-22 WO PCT/US2007/069411 patent/WO2007137244A1/en active Application Filing
- 2007-05-22 PL PL07797634T patent/PL2028937T5/pl unknown
- 2007-05-22 CA CA2666293A patent/CA2666293C/en active Active
- 2007-05-22 KR KR1020087029431A patent/KR101571163B1/ko active IP Right Grant
- 2007-05-22 KR KR1020157017784A patent/KR101587394B1/ko active IP Right Grant
- 2007-05-22 US US12/301,689 patent/US20090105333A1/en not_active Abandoned
- 2007-05-22 CA CA2950087A patent/CA2950087A1/en not_active Abandoned
- 2007-05-22 MX MX2008014841A patent/MX2008014841A/es active IP Right Grant
- 2007-05-22 AU AU2007253701A patent/AU2007253701A1/en not_active Abandoned
- 2007-05-22 EP EP07797634.8A patent/EP2028937B2/en active Active
- 2007-05-22 RU RU2008150622/15A patent/RU2488392C2/ru active
- 2007-05-22 JP JP2009512250A patent/JP2009538332A/ja active Pending
- 2007-05-22 PT PT77976348T patent/PT2028937E/pt unknown
- 2007-05-22 BR BRPI0712206-3A patent/BRPI0712206A2/pt not_active Application Discontinuation
- 2007-05-22 DK DK07797634.8T patent/DK2028937T4/en active
-
2008
- 2008-11-07 ZA ZA200809529A patent/ZA200809529B/xx unknown
-
2013
- 2013-07-17 AU AU2013207585A patent/AU2013207585B2/en active Active
-
2014
- 2014-08-21 JP JP2014168550A patent/JP2015013875A/ja active Pending
- 2014-11-27 US US14/555,676 patent/US20150080464A1/en not_active Abandoned
-
2015
- 2015-04-28 CY CY20151100389T patent/CY1120433T1/el unknown
-
2016
- 2016-02-12 NL NL300795C patent/NL300795I2/nl unknown
- 2016-08-19 US US15/241,178 patent/US20160354337A1/en not_active Abandoned
- 2016-09-20 JP JP2016183125A patent/JP6306114B2/ja active Active
-
2018
- 2018-03-07 JP JP2018040371A patent/JP6480050B2/ja active Active
- 2018-04-27 US US15/964,693 patent/US20180243258A1/en not_active Abandoned
-
2019
- 2019-02-06 JP JP2019019546A patent/JP6659072B2/ja active Active
-
2020
- 2020-09-01 US US17/009,457 patent/US20200397741A1/en not_active Abandoned
-
2021
- 2021-11-24 AU AU2021273588A patent/AU2021273588B2/en active Active
-
2022
- 2022-10-14 US US17/655,929 patent/US20230021493A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200809529B (en) | Melatonin agonist treatment | |
AU2013207585A1 (en) | Melatonin agonist treatment | |
GB0606604D0 (en) | Treatment apparatus | |
GB0624874D0 (en) | Treatment | |
EP1996182A4 (en) | CANCER TREATMENT WITH GAMMA SECRETASE INHIBITORS | |
EP2106814A4 (en) | TREATMENT DEVICE | |
IL196559A0 (en) | Combination therapy | |
GB0610501D0 (en) | Garbage-containing apparatus | |
GB0608334D0 (en) | Apparatus | |
GB2436010B (en) | Therapy device | |
EP2127715A4 (en) | HORIZONTALROHRSEDIMENTATIONSTRENNVORRICHTUNG | |
GB0600692D0 (en) | Well treatment | |
IL196556A0 (en) | Combination therapy | |
EP2054061A4 (en) | COMBINATION THERAPY | |
GB0605445D0 (en) | Opphalmic apparatus | |
GB2438385B (en) | Surface treatment device | |
ZA200902203B (en) | Combination therapy | |
GB0607952D0 (en) | Novel treatment | |
EP2133035A4 (en) | TREATMENT DEVICE | |
GB0604460D0 (en) | Treatment | |
GB0601181D0 (en) | Apparatus | |
EP2088083A4 (en) | PACKING STRIP DEVICE | |
IL196041A0 (en) | 5-htp combination therapy | |
GB0610716D0 (en) | Apparatus | |
GB0607678D0 (en) | Apparatus |